Synopsis
Podcast by Dr. Cush
Episodes
-
![Pain in RA: Different Drugs for Different Mechanisms]()
Pain in RA: Different Drugs for Different Mechanisms
13/06/2024 Duration: 06minDr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
-
![JAK Inhibitors for New Indications]()
JAK Inhibitors for New Indications
13/06/2024 Duration: 02minDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
-
![Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA]()
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
13/06/2024 Duration: 06minDr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
-
![Treat to Target Outcomes in Early AxSpA]()
Treat to Target Outcomes in Early AxSpA
13/06/2024 Duration: 07minDr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
-
![Does Telemonitoring in SpA Work?]()
Does Telemonitoring in SpA Work?
13/06/2024 Duration: 05minDr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
-
![PsA Treatment: is Earlier Better?]()
PsA Treatment: is Earlier Better?
13/06/2024 Duration: 05minDr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
-
![JAK Inhibitors for New Indications]()
JAK Inhibitors for New Indications
13/06/2024 Duration: 02minDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
-
![Transition from Psoriasis to PsA: Can we Prevent It?]()
Transition from Psoriasis to PsA: Can we Prevent It?
13/06/2024 Duration: 04minDr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
-
![EULAR 2024 Daily Recap - Days 1 2]()
EULAR 2024 Daily Recap - Days 1 & 2
13/06/2024 Duration: 41minModerated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey
-
![Mechanistic Promise in RA Doesn’t Always Mean Actual Gain]()
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
13/06/2024 Duration: 04minDr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
-
![The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis]()
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
13/06/2024 Duration: 04minDr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
-
![Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?]()
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
13/06/2024 Duration: 05minDr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
-
![Voclosporin and Steroids in Lupus Nephritis]()
Voclosporin and Steroids in Lupus Nephritis
13/06/2024 Duration: 03minDr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
-
![3 Big Lupus Themes from EULAR 2024]()
3 Big Lupus Themes from EULAR 2024
13/06/2024 Duration: 02minDr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.
-
![Does B Cell Depletion Matter?]()
Does B Cell Depletion Matter?
13/06/2024 Duration: 05minDrs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
-
![Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?]()
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
13/06/2024 Duration: 03minDr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab
-
![Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?]()
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
13/06/2024 Duration: 05minDr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
-
![Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?]()
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
13/06/2024 Duration: 05minDr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
-
![Is Cannabis Safe? (6.7.2024)]()
Is Cannabis Safe? (6.7.2024)
07/06/2024 Duration: 21minDr. Jack Cush reviews FDA approval, news and journal articles -- Its the week before EULAR 2024 in Vienna!!
-
![ACR’s Run at Goliath (PCPs) (5.31.2024)]()
ACR’s Run at Goliath (PCPs) (5.31.2024)
31/05/2024 Duration: 18minDr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APP's - what do you think?
